From USFDA
Dr Reddys Laboratories announced that its US subsidiary, Promius Pharma, LLC, U.S., has received approval for Sernivo (betamethasone dipropionate) Spray, 0.05%, from the United States Food and Drug Administration. Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years or older. The commercial launch of the product is planned for the coming quarter.Powered by Capital Market - Live News
